Tag: Acromegaly
Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal
Sarantis Livadas, Dimitrios J. Hadjidakis, Maria I. Argyropoulou, Maria Stamatelatou, Dimitrios Kelekis, Sotirios A. Raptis
Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. We are aware of only three reported cases of complete shrinkage of a pituitary adenoma after long-term analogue administration…
Growth hormone binding protein and acid labile subunit levels in the assessment of acromegaly treatment
Marinella Tzanela, Marieta Christoforaki, Lida Papastathopoulou, Dimitra Vassiliadi, Effie Botoula, Panagiotis Trivizas, Nikos C. Thalassinos
Objective: Post-treatment monitoring of acromegalic patients is a matter of controversy, as discrepancies between GH and IGF-I levels have been reported. The aim of our study was to evaluate the role of acid-labile subunit (ALS), a component of the 150 kD IGF-I/IGFBP-3/ALS complex, and the growth hormone binding protein (GHBP) in the follow-up of patients with acromegaly after therapeutic intervention…
Pegvisomant: a new treatment modality for acromegaly
Niki Karavitaki, John AH Wass
Acromegaly, a multisystemic disease resulting from excessive growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels in adults, is associated with a two-to-threefold increase in mortality. The available treatment options (surgery, radiotherapy and medical treatment with somatostatin analogues or dopamine agonists) fail to achieve the currently accepted goals of therapy in a substantial number of patients …
Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center
Monica Livia Gheorghiu, Simona Găloiu, Mădălina Vintilă, Mariana Purice, Dan Hortopan, Anda Dumitraşcu, Mihail Coculescu, Cătălina Poiană
BACKGROUND: Somatostatin analogs (SSA) are now considered standard therapy for acromegaly, as primary or adjunctive treatment after pituitary surgery. OBJECTIVE: To evaluate the efficacy of SSA and the effect of dose escalation in non-operated patients with acromegaly as compared to patients treated after pituitary surgery in a Romanian tertiary care center …
Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control
Ilan Shimon, Wolfgang Saeger, Luiz Eduardo Wildemberg, Monica R. Gadelha
OBJECTIVE: To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels. METHODS: We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched …